The not-for-profit healthcare landscape is rapidly changing. To stay relevant, health systems are demonstrating innovation and resilience in the face of evolving challenges, with many focusing on their core identities, community impact, technological advancements and operational efficiency.
At the recent 43rd annual J.P. Morgan Healthcare Conference, presenters from some of the largest integrated providers in the U.S. shared their strategies and visions for the future of the industry, emphasizing their commitment to delivering consumer-centric, high-quality care. Read on to discover some of the key themes shaping not-for-profit healthcare in 2025 and beyond.
1. National scale and influence with regional relevance
Achieving scale has long been a common theme for health systems as size can be a determinant of performance. Scale also equates to national influence, leading to opportunities to partner with large, innovative companies, as well as creating healthier balance sheets for further investments.
Increasingly, the importance of achieving the right kind of scale is taking centerstage, with systems focused on investing in growth markets and making difficult decisions to rightsize their portfolios. Market expansion and divestiture strategies now revolve around the primary goal of becoming better, not just bigger.
2. Consumerism is an unstoppable force
Health systems have been shifting toward consumer-centric care models that prioritize the patient experience and convenience for some time now, such as by offering more outpatient and virtual care options. Some providers are highlighting the importance of personalization and exploring how data will transform the future, while others are seeking to stay aligned with an aging consumer base. Overall, it is clear that consumer advances will accelerate with AI.
3. Partnership and collaborations: Solutions perform better at scale
Today, collaborations with health systems, academic institutions and other players across the continuum of care are more prevalent than ever. Partnerships are aimed at enhancing service offerings, sharing resources and driving innovation, and they are expected to increase as healthcare organizations look for ways to gain value out of scale without full asset mergers.
4. The transformative power of AI
When it comes to AI, health systems are moving from implementation to seeing real returns on tech-enabled scalability. Many providers are focused on integrating technology to enhance patient care and operational efficiency. Some have managed to reduce administrative work by up to four hours a day, while others have freed up capacity for more patients without needing new investments in facilities. Overall, the utilization of AI is expected to increase exponentially across the industry over the next several years.
5. Financial resiliency and operational rigor
Health systems are emphasizing financial stability through strategic investments, cost management and capital allocation, resulting in improved margins and recurring synergies. Overall, the industry has seen an improvement in operations, but there continues to be haves and have-nots, with performance being influenced by market relevance, geography and size.
What are the other trends defining the future of not-for-profit healthcare?
Contact your J.P. Morgan representative to find out more.
Related insights
Healthcare
Healthcare Conference
Insights from J.P. Morgan Global Research on the major themes in healthcare in 2025 and the future of biotech.
Banking
Public Finance
J.P. Morgan’s Public Finance group offers financial solutions to keep some of the world’s most essential services running. Learn more about public finance.
Investment Banking
Investment Banking
Providing investment banking solutions, including mergers and acquisitions, capital raising and risk management, for a broad range of corporations, institutions and governments.
This document was prepared exclusively for the benefit and internal use of the J.P. Morgan client to whom it is directly addressed and delivered (including such client’s subsidiaries, the “Company”) in order to assist the Company in evaluating, on a preliminary basis, the feasibility of a possible transaction or transactions and does not carry any right of publication or disclosure, in whole or in part, to any other party. This document is for discussion purposes only and is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing provided by J.P. Morgan. Neither this document nor any of its contents may be disclosed or used for any other purpose without the prior written consent of J.P. Morgan. Additionally, this presentation may contain content initially generated by AI or other automated technologies.
The information in this document is based upon any management forecasts supplied to us and reflects prevailing conditions and our views as of this date, all of which are accordingly subject to change. J.P. Morgan’s opinions and estimates constitute J.P. Morgan’s judgment and should be regarded as indicative, preliminary and for illustrative purposes only. In preparing this document, we have relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources or which was provided to us by or on behalf of the Company or which was otherwise reviewed by us. In addition, our analyses are not and do not purport to be appraisals of the assets, stock, or business of the Company or any other entity. J.P. Morgan makes no representations as to the actual value which may be received in connection with a transaction nor the legal, tax or accounting effects of consummating a transaction. Unless expressly contemplated hereby, the information in this document does not take into account the effects of a possible transaction or transactions involving an actual or potential change of control, which may have significant valuation and other effects.
Notwithstanding anything herein to the contrary, the Company and each of its employees, representatives or other agents may disclose to any and all persons, without limitation of any kind, the U.S. federal and state income tax treatment and the U.S. federal and state income tax structure of the transactions contemplated hereby and all materials of any kind (including opinions or other tax analyses) that are provided to the Company relating to such tax treatment and tax structure insofar as such treatment and/or structure relates to a U.S. federal or state income tax strategy provided to the Company by J.P. Morgan. J.P. Morgan's policies on data privacy can be found at http://www.jpmorgan.com/pages/privacy.
J.P. Morgan is a party to the SEC Research Settlement and as such, is generally not permitted to utilize the firm's research capabilities in pitching for investment banking business. All views contained in this presentation are the views of J.P. Morgan’s Investment Bank, not the Research Department. J.P. Morgan’s policies prohibit employees from offering, directly or indirectly, a favorable research rating or specific price target, or offering to change a rating or price target, to a subject company as consideration or inducement for the receipt of business or for compensation. J.P. Morgan also prohibits its research analysts from being compensated for involvement in investment banking transactions except to the extent that such participation is intended to benefit investors.
Changes to Interbank Offered Rates (IBORs) and other benchmark rates: Certain interest rate benchmarks are, or may in the future become, subject to ongoing international, national and other regulatory guidance, reform and proposals for reform. For more information, please consult: https://www.jpmorgan.com/global/disclosures/interbank_offered_rates
JPMorgan Chase & Co. and its affiliates do not provide tax advice. Accordingly, any discussion of U.S. tax matters included herein (including any attachments) is not intended or written to be used, and cannot be used, in connection with the promotion, marketing or recommendation by anyone not affiliated with JPMorgan Chase & Co. of any of the matters addressed herein or for the purpose of avoiding U.S. tax-related penalties.
J.P. Morgan is a marketing name for investment businesses of JPMorgan Chase & Co. and its subsidiaries and affiliates worldwide. Securities, syndicated loan arranging, financial advisory, lending, derivatives and other investment banking and commercial banking activities are performed by a combination of J.P. Morgan Securities LLC, J.P. Morgan Securities plc, J.P. Morgan SE, JPMorgan Chase Bank, N.A. and the appropriately licensed subsidiaries and affiliates of JPMorgan Chase & Co. worldwide. J.P. Morgan deal team members may be employees of any of the foregoing entities. J.P. Morgan Securities plc is authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. J.P. Morgan SE is authorised as a credit institution by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB).
For information on any J.P. Morgan German legal entity see: https://www.jpmorgan.com/country/US/en/disclosures/legal-entity-information#germany.
For information on any other J.P. Morgan legal entity see: https://www.jpmorgan.com/country/GB/EN/disclosures/investment-bank-legal-entity-disclosures.
JPMS LLC intermediates securities transactions effected by its non-U.S. affiliates for or with its U.S. clients when appropriate and in accordance with Rule 15a-6 under the Securities Exchange Act of 1934. Please consult: www.jpmorgan.com/securities-transactions
This document does not constitute a commitment by any J.P. Morgan entity to underwrite, subscribe for or place any securities or to extend or arrange credit or to provide any other services.
Copyright 2025 JPMorgan Chase & Co. All rights reserved.